This is a randomized phase II ComboMATCH study evaluating AMG 510 (sotorasib) with or without panitumumab in KRAS G12C-mutant advanced solid tumors. The trial targets cancers that may have metastasized from the primary site to regional structures, lymph nodes, or distant sites.
Sotorasib is a KRAS inhibitor designed to block signaling from the mutant KRAS G12C protein, aiming to reduce cancer cell proliferation and progression. Panitumumab is a monoclonal antibody intended to slow or halt tumor growth by targeting EGFR pathways.
The trial investigates whether adding panitumumab to sotorasib improves antitumor activity compared with sotorasib alone in patients with KRAS G12C-mutant advanced or metastatic solid tumors. Study design notes: interventional, phase II, randomized with two arms (sotorasib monotherapy vs combination with panitumumab).
Primary purpose is treatment. Estimated enrollment is 105 participants.
Status is recruiting, with an estimated completion date in late 2028. The source provides no efficacy or safety data; uncertainty remains regarding comparative effectiveness and tolerability until results mature.
Uncertainty remains regarding comparative efficacy, safety, and long-term impact, as results are not reported.